Misiu, I agree. The number we had before was 2

Misiu,

I agree. The number we had before was 228:114 (342 in total). Also, the primary end point was mortality rate @ 2 weeks. From release 4/1/2020:

Quote:

---

CytoDyn expects to enroll patients in both the Mild-to-Moderately Ill and Severely Ill protocols very quickly under the same IND that was provided with a “safe to proceed” letter from the FDA. The new protocol for Severely Ill COVID-19 patients is for 342 patients, double blinded with 2:1 ratio. Patients enrolled in this trial are expected to be administered leronlimab for two weeks with the primary endpoint being the mortality rate at 14 days.

---

Now this states:

Quote:

---

Patients enrolled in this trial are expected to be administered leronlimab for two weeks with the primary endpoint being the mortality rate at 28 days and a secondary endpoint of mortality rate at 14 days. The Company will perform an interim analysis on the data from 50 patients.

---

Not sure if further talks with FDA changed the trial design CYDY was proposing (quite possible) or there is a mistake (unlikely). However, I think this is the last word and it makes sense from the perspective of duration, if Leronlimab is administered for two weeks one needs to wait a bit longer for the last administration to take effect (at least one more week as per Dr. B. Patterson where immunological response restoration was seen achieved in 7 days).

TBD